COVID19 Vaccine Made By Novavax Inc

Another COVID19 Vaccine Made By Novavax Inc Reaches The Final Stage Testing In The US

Health

After Pfizer and Moderna vaccines, another COVID19 vaccine manufactured by Novavax Inc. has reached the final stage of clinical testing in the US. The company has revealed that it needs around 30000 volunteers to test the efficacy and safety of the vaccine. The company officials have said that this vaccine will be proved a different one than its competitors such as Pfizer and Moderna. As the US has rolled out limited supplies of the first vaccines, a huge study of testing another COVID19 vaccine is underway. The company which has been rescued by $1.6 billion by the Trump administration’s Operation Warp Speed Program is going to launch the last stage efficacy trial in the US and Mexico soon. Novavax has fully enrolled its last stage trial in the UK in association with Britain’s vaccine task force with more than 15000 participants. The data of this trail will be used to back its submission for European regulatory approval. As per the report, the company is the fifth firm to start the large-scale clinical trial of its vaccine in the US. The vaccine made by Novavax is being developed at Fujifilm Diosynth Biotechnologies (FDB) in Morrisville.
The company has delayed its large-scale US trial many times, as the company has been struggling to scale up the manufacturing of the vaccine. The UK trial of the Novavax vaccine as well has not released any result yet. However, the outcomes of the first human trial of the vaccine have been quite promising. It has been 30 years since the company has been venturing into vaccine manufacturing, but it has never obtained approval for any of its vaccines. Health experts are waiting to see whether the jinx will be broken this time. The Maryland-based biotech firm is going to the final stage trial at 115 sites in the US. In the clinical trial, around two-thirds of 30000 participants will be given the vaccine and the rest one third will receive a placebo. The company has launched its phase 2 trial in South Africa as well. The Novavax COVID19 candidate is one of two protein subunit shots. The other subunit vaccine has been created by Sanofi Pasteur. The US government has put billions of dollars on vaccine making giant Sanofi Pasteur. The vaccine subunit made by Sanofi Pasteur has tiny lipid particles studded with the replicas of the spike protein of the SARS-CoV-2 virus. Experts have said that vaccine lipids do not have the polymer polyethylene glycol (PEG) which has led to allergic reactions due to its presence in other COVID19 vaccines. The PEG has been replaced by an immune-boosting plant-based compound called Saponin, said the experts.
The company has agreed that the availability of two vaccines by Pfizer-BioNtech and Moderna, which have been proved more than 90 percent effective, safe, and approved, by the US Food and Drug Administration (FDA) might refrain people from enrolling in its US trial. The company officials have said that people who are considering the trail might have many questions about their ability to get an approved vaccine when it is available. They have assured people that enrolling in their vaccine trial in the US will not negatively affect their ability to be inoculated at the appropriate time. As per the report, the Novavax vaccine does not need special ultra-cool chambers for transportation and distribution. The officials of the company have said that it will remain stable between 2 to 8 degrees Celsius.

Leave a Reply

Your email address will not be published. Required fields are marked *